Lakefront Biotherapeutics American Depositary Shares
LKFT
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
Last trade$34.77
Day change-$0.025 (-0.07%)
Day range$34.49 – $35.19
Volume188,293
Market cap$2.29B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for LKFT.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for LKFT.
Recent news
Company coverage with links to the original publishers.
Lakefront Biotherapeutics announced a new €50 million share repurchase program on November 16, 2026, following the completion of its initial €50 million program in October 2026. The company repurchased approximately 1.99 million shares under the initial program and believes its current share price undervalues the business. The new program will run through March 31, 2027, with Morgan Stanley acting as the independent financial intermediary.
Lakefront Biotherapeutics NV has announced a new €50 million share buyback program following the completion of its initial €50 million program. The company will repurchase up to 4.6 million shares through Morgan Stanley on Euronext between November 16, 2026 and March 31, 2027. Management believes the current stock price undervalues the company and its pipeline prospects.
The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.
Lakefront Biotherapeutics (LKFT) has formed a golden cross technical pattern, with its 50-day moving average crossing above its 200-day moving average, suggesting a potential bullish breakout. The stock has risen 13.7% over the past four weeks and holds a #2 (Buy) rating on the Zacks Rank. Earnings estimates have also been revised upward, supporting the bullish outlook.
Lakefront Biotherapeutics (LKFT) has been upgraded to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The upgrade reflects improved earnings outlook and positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation. Analysts have raised consensus estimates by 89.3% over the past three months.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.